ATHE News and Press, Alterity Therapeutics Limited From 06/23/22

Australian biotech Alterity Therapeutics (NASDAQ:ATHE) announced on Thursday that the authorities in Italy cleared a Phase 2 trial for its lead drug candidate ATH434 in multiple system atrophy (MSA), a rare Parkinsonian disorder. The randomized, double-blind study will be designed to evaluate...

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy PR Newswire MELBOURNE, Australia and SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "t...

NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...

NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...

MELBOURNE, Australia and SAN FRANCISCO, June 20, 2022 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, to...

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy PR Newswire Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE...

Alterity Therapeutics (NASDAQ:ATHE) said the U.K.'s Medicines & Healthcare products Regulatory Agency (MHRA) accepted its application to conduct a phase 2 trial of ATH434 in Multiple System Atrophy (MSA). MSA is a rare neurological disorder affecting the body's involuntary functions, incl...

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom PR Newswire MELBOURNE, Australia , April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "t...

Alterity Therapeutics Limited (NASDAQ:ATHE) traded today at a new 52-week high of $6.12. So far today approximately 132.7 million shares have been exchanged, as compared to an average 30-day volume of 106,000 shares. In the past 52 weeks, shares of Alterity Therapeutics Limited have trad...

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting PR Newswire The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia and SAN FRANCISCO , ...